Cialis (tadalafil): A new treatment for erectile dysfunction

Hospital Medicine

Volumn 64, Issue 10, 2003, Pages 589-592

  Minhas, S ^a   Kalsi, J S ^a   Ralph, D J ^a  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; NITRATE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL; CARBOLINE DERIVATIVE;

BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIABETES MELLITUS; DRUG ALCOHOL INTERACTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DYSPNEA; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; HEADACHE; HEART DEATH; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HUMAN; MYALGIA; NOSE CONGESTION; PENIS ERECTION; REVIEW; SIDE EFFECT; VISION; DRUG EFFECT; IMPOTENCE; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY;

CARBOLINES; CLINICAL TRIALS, PHASE III; HUMANS; IMPOTENCE; MALE; MULTICENTER STUDIES; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS;

EID: 0642372924     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.10.2323     Document Type: Review

References (13)

1. Angulo J, Gadau M, Fernandez A et al (2001) Tadalafil (IC351) enhances nitric oxide-mediated relaxation of human arterial and trabecular smooth muscle. Presented at the European Association for the Study of Diabetes (EASD), Glasgow, Scotland
2. Aytac IA, McKinlay JB, Krane RJ (1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84: 450-6
3. Brock GB, McMahon CG, Chen KK et al (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168(4 Pt 1): 1332-6
4. Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56(6): 453-9
5. Hutter AM, Kloner RA, Watkins VS, Costigan T, Bedding A, Mitchell MI, Emmick JT (2002) Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor. Presented at the American Society of Haematologists (ASH), New York City, USA
6. Jackson G, Keltai M, Gillies H, Czorniak M, Keating Z (2002) Viagra is well tolerated by subjects with stable angina and erectile dysfunction during incremental treadmill exercise. Eur Urol Suppl 1: 596P
7. Kloner RA, Emmick J, Bedding A, Humen D (2002) Pharmacodynamic interactions between tadalafil and nitrates. Presented at the American College of Cardiology (ACC), Atlanta, Georgia, USA
8. National Institutes of Health (1992) Impotence. NIH Consensus Statement 10: 1-33
9. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC (2001) On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13(1): 2-9
10. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M (2001a) The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 13(Suppl 4): S43
11. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M (2001b) Dose-normalised pharmacokinetics of tadalafil (IC351) administered as a single dose to health volunteers. Int J Impot Res 13(Suppl 4): S43
12. Rendell MS, Rajfer J, Wicker PA, Smith MD (1999) Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial: Sildenafil Diabetes Study Group. JAMA 281: 421-6
13. Saenz De Tejada I, Anglin G, Knight JR, Emmick JT (2002) Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 25(12): 2159-64